Dual Benefits of Oral Tranexamic Acid: Reducing Melasma Severity and Inflammation
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.70257 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Abdullah Demirbas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Kocaeli University Faculty of Medicine, Department of Dermatology, Kocaeli, Turkey. Hauptthemen laut MEDLINE: Tranexamic Acid, Melanosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Melasma is a chronic hyperpigmentation disorder influenced by hormonal factors, ultraviolet exposure, and inflammation. While oral tranexamic acid ( TXA ) is an established treatment, its effects on systemic inflammation remain unclear.
Aims
This study aimed to evaluate the impact of TXA on melasma severity and inflammatory markers.
Methods
This retrospective study included 80 melasma patients and 80 healthy controls. Patients received oral TXA (500 mg/day) for 3 months. Melasma severity was assessed using the Melasma Area and Severity Index ( MASI ), and inflammatory markers (monocyte, neutrophil, lymphocyte, HDL , MHR , MLR , NLR ) were measured at baseline, Month 1, and Month 3. Changes within the melasma group and comparisons with controls were analyzed.
Results
At 3 months, melasma severity significantly improved, with a 65.1% reduction in MASI (from 12.9 to 4.5, p < 0.001). Monocyte, neutrophil, MHR , MLR , and NLR levels significantly decreased, while HDL and lymphocyte levels increased ( p < 0.001). Compared to controls, baseline inflammatory marker levels differed significantly; however, at month 3, only monocyte, MHR , and HDL remained significantly different ( p < 0.05). Regression analysis identified NLR and HDL as significant predictors of melasma severity reduction ( p = 0.045 and p = 0.011, respectively).
Conclusion
Oral TXA not only improved melasma severity but also modulated systemic inflammation. The association between NLR , HDL , and treatment response suggests their potential as biomarkers for monitoring therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kocaeli University Faculty of Medicine, Department of Dermatology, Kocaeli, Turkey.
- Kocaeli City Hospital, Department of Dermatology, Kocaeli, Turkey.
- Dicle University Faculty of Medicine, Department of Dermatology, Diyarbakır, Turkey.
ORCID-Profile: Mustafa Esen
Zitieren
APA
Demirbas, A., Ulutas Demirbas, G., Diremsizoglu, E., & Esen, M. (2025). Dual Benefits of Oral Tranexamic Acid: Reducing Melasma Severity and Inflammation. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70257
Vancouver
Demirbas A, Ulutas Demirbas G, Diremsizoglu E, Esen M. Dual Benefits of Oral Tranexamic Acid: Reducing Melasma Severity and Inflammation. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70257
BibTeX
@article{Demirbas2025,
author = {Demirbas, Abdullah and Ulutas Demirbas, Gozde and Diremsizoglu, Esin and Esen, Mustafa},
title = {Dual Benefits of Oral Tranexamic Acid: Reducing Melasma Severity and Inflammation},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.70257}
}
EUVIMED